Exhibitors on the QTCN booth at BIO 2008 in San Diego

As the NSW Parliament debates therapeutic cloning, the hunt for alternative sources of pluripotent stem cells is on.

Bionomics has some good news to take to BIO 2007 from preclinical trials of its candidate vascular disruption agent.

"It is not that stem cell transplantation doesn't work, it is just that we need more work to figure it out." With this kind of simple optimism, and a little green jasmine tea, Professor Brent Reynolds chatted with Fiona Wylie about life, coincidence and the use of neural stem cells to treat spinal cord injury.

Is it possible to re-awaken dormant pathways in humans to regenerate tissue? Graeme O'Neill talks to Professor Randall Moon about the Wnt family of cell-signalling proteins.

Bone disease biopharmaceutical company Bone Medical (ASX:BNE) has issued a prospectus with the aim of raising approximately AUD$3.1 million.

Bionomics (ASX:BNO) has acquired unlisted Melbourne discovery company Iliad Chemicals for 40.9 million Bionomics shares - approximately AUD$6.1 million at current market prices.

Avexa (ASX:AVX) consultant James Sawyer outlined to investors this week the company's plans for its Phase IIb clinical trial of AVX754, the HIV drug it recently acquired from UK company Shire Pharmaceuticals.

CSL (ASX:CSL) has completed the sale of its JRH Biosciences division to Sigma-Aldrich for US$370 million, and Bionomics (ASX:BNO) has completed the acquisition of a French contract research organisation.

Bionomics (ASX: BNO) CEO Deborah Rathjen outlined the company's strategy for growth at a briefing this week, noting that the company aimed to become a AUD$200 million company within three years.

South Australian biotech Bionomics (ASX:BNO) is to pay more than AUD$2 million in cash and kind for Neurofit, a small contract research company that specialises in testing candidate drugs for central nervous system (CNS) disorders in cellular and animals models.